Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06730542 · ClinicalTrials.gov registry record · Phase 1
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
A Phase 1 study of CNS Lymphoma, sponsored by Juan P. Alderuccio, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06730542 is a Phase 1 study of CNS Lymphoma that is actively recruiting participants, run by Juan P. Alderuccio, MD. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06730542, a Phase 1 study of CNS Lymphoma, is actively recruiting participants, sponsored by Juan P. Alderuccio, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to is to determine the effects (good and bad) of Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in patients with Secondary Central Nervous System (CNS) Lymphoma.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Cyclophosphamide
- DRUG Rituximab
- DRUG Polatuzumab Vedotin
- DRUG Methotrexate
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-04-17 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06730542
The ClinicalTrials.gov registry entry for NCT06730542 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Juan P. Alderuccio, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CNS Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Zanubrutinib is the first listed.
NCT06730542 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06730542 about?
NCT06730542 is a clinical study titled "Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma". The purpose of this study is to is to determine the effects (good and bad) of Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in patients with Secondary Central Nervous System (CNS) Lymphoma.
What is the current status of trial NCT06730542?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-04-17. Estimated completion is 2030-04-30.
What conditions does trial NCT06730542 study?
This clinical trial studies the following conditions: CNS Lymphoma.
What interventions are being tested in trial NCT06730542?
The interventions under investigation include: Zanubrutinib (DRUG), Cyclophosphamide (DRUG), Rituximab (DRUG), Polatuzumab Vedotin (DRUG), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT06730542?
This trial is sponsored by Juan P. Alderuccio, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06730542 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CNS Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.